enGene raises $6.4 M for insulin production technology

Guest Contributor
March 27, 2008

Vancouver-based enGene Inc has raised US $6.4 million to further develop its Gut Endocrine-cell Modification System (GEMS) technology for the treatment of diabetes and anticipates further series ‘B' financing later this year. The privately held company received the financing from Saad Investments Co Ltd, Masa Life Science Ventures LP and several private investors. GEMS insulin allows a patient to produce insulin from his/her own cells by utilizing the therapeutic protein production capacity of healthy cells in the duodenum by delivering a gene construct in a novel, non-viral vector. Other applications include inflammatory bowel disease, obesity and anemia....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.